Mayday University Hospital awarded 3 stars in NHS performance rating

Posted:
4
August 2005

Unit At Mayday

We are delighted to announce that Mayday University Hospital NHS Trust was recently issued an annual performance rating of 3 stars, which places them in the top 28% of Trusts in the UK. This is the highest rating available under the Healthcare Commission rating scheme.The performance rating reports are designed to review the key factors the Trusts need to achieve to deliver a better service to patients. This includes Patient Focus, Clinical Focus, Capacity and Capability Focus, Access to Quality Services, Improving Health and Services Provision. Overall, the Healthcare Commission report concluded that Mayday Hospital is delivering in each of these areas.Dr Jörg Täubel, Managing Director of Richmond Pharmacology, commented: “We have been working closely with the Trust over the past 18 months to facilitate the move of our second unit to Mayday hospital. Throughout this period of time I have been consistently impressed with the quality I experienced when working with the Trust. I am very pleased that this standard has been recognized by the Healthcare Commission. It's reassuring to conduct our trials within such a well managed, acute setting.”Richmond opened the new unit within Mayday University Hospital in May 2005.To view the Healthcare Commission report on Mayday click here.

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more